RARITAN, N.J., April 18, 2011 /PRNewswire/ -- Virco Lab, Inc., the U.S. affiliate of Virco BVBA, today announced that AVIGA™, an electronic health record (EHR) designed specifically to meet the complex disease-management needs of health care providers who are treating people living with HIV/AIDS, has achieved modular (partial) certification in accordance with the "Meaningful Use Stage 1" requirements in the U.S.
Tested and certified under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Testing and Certification Body (ONC-ATCB) program, the certification deems that the compliant components of the EHR software are eligible for providers to qualify for funding under the American Recovery and Reinvestment Act (ARRA) during 2011/2012(1).
"The certification validates that AVIGA™ has the capacity to assist clinicians in demonstrating the meaningful use requirements that are necessary to qualify for ARRA incentives," said David Rebey, Head of U.S. Business Operations, Virco Lab, Inc. "We believe AVIGA™ will provide specific solutions that address the needs of HIV clinicians in managing patient healthcare in this new era of HITECH(2) and digital medicine. We are pleased we have reached this major milestone in the requirement process and are actively working toward full certification this summer."
Virco BVBA acquired the electronic medical record LABTRACKER™ HIV in December 2009 from its originator company, Ground Zero Software. Since the acquisition, Virco has completely redeveloped the platform and is now set to launch two new web-based product offerings, AVIGA™ and AVIGA REPORTER™, over the coming months. AVIGA™ is a full electronic health record for clinics with no current EHR system installed, and AVIGA REPORTER™ is designed to provide HIV-specific functionality, research and reporting capabilities that are interoperable with existing EHRs already installed.
About Virco BVBA and Virco Lab, Inc.
Virco Lab, Inc. is the U.S. affiliate of Virco BVBA, a global diagnostic and healthcare solutions company based in Belgium, and a pioneer and leader in HIV resistance interpretation. In addition to providing resistance interpretation with the use of its virco®TYPE HIV-1, education and facilitating access to resistance interpretation worldwide, it actively collaborates with hospitals and academic institutions in researching solutions with virological and clinical relevance in HIV, HCV and other infectious diseases.
Virco's mission is to facilitate personalized clinical decision-making via advanced diagnostic and bioinformatic tools. Since the acquisition of LABTRACKER HIV™ in December 2009, Virco Lab, Inc. is now providing support and service for current LABTRACKER HIV™ clients in the U.S. while redevelopment and planning are underway for the new and improved applications, AVIGA™ and AVIGA REPORTER™.
(1) THE INFORMATION CONTAINED IN THIS DOCUMENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND REPRESENTS NO STATEMENT, PROMISE, OR GUARANTEE BY VIRCO CONCERNING RECEIPT OR PAYMENT OF GOVERNMENT INCENTIVES. We strongly recommend that you consult with your counsel for advice on incentive eligibility.
(2) Health Information Technology for Economic and Clinical Health Act
Media Contact (U.S.):
David J. Rebey
Head of US Business Operations
Virco Lab, Inc.
Mobile Phone: 908-432-9137
Media Contact (Global):
Global Marketing Director
Mobile Phone: +32 475 554423
Policy and Payment
Virco Lab, Inc.
Mobile Phone: 631-786-4720
SOURCE Virco Lab, Inc.